Lymphatic Circulation #3: Failure in Fontan Circulation

Date
April 8, 2026
URL
https://x.com/WithAScalpel/status/2041847390160711695?s=20
Categories
Lymphatic CirculationIntensive CareFontan

Lymphatic Circulation #3: Failure in Fontan Circulation

image

Lymphatic failure is a major extracardiac consequence of the Fontan circulation. Because pulmonary blood flow occurs without a subpulmonary ventricle, the Fontan pathway depends on chronically elevated systemic venous pressure to drive blood across the pulmonary vascular bed. This hemodynamic arrangement creates an unfavorable downstream pressure for lymphatic return and, over time, imposes a persistent afterload on the lymphatic system [1,2]. The result is impaired central lymphatic drainage, lymphatic congestion, collateral formation, and leakage of lymph into low-pressure compartments rather than efficient return to the venous circulation. (PubMed)

1. Pathophysiologic Basis

Under normal conditions, lymphatic flow depends on a favorable pressure gradient between the peripheral tissues and the central venous system. In the Fontan circulation, this gradient is blunted by chronically elevated central venous pressure (CVP). At the same time, venous congestion increases interstitial fluid production, thereby increasing lymphatic load precisely when lymphatic egress is most impaired [1,2]. In this setting, the lymphatic system is not merely congested passively; it undergoes structural and functional remodeling, including dilation, tortuosity, collateralization, and abnormal perfusion into adjacent organs [1,3,4]. (PubMed)

Another important contributor is the loss of efficient cardiopulmonary energy transfer that characterizes the normal biventricular circulation. In Fontan physiology, reduced pulsatility and diminished diastolic assistance to venous return further limit effective lymphatic emptying. Thus, lymphatic failure in Fontan patients reflects a combination of elevated venous afterload, increased lymph production, and impaired lymph transport capacity [1,2]. (PubMed)

2. From Hemodynamic Stress to Clinical Lymphatic Failure

Once central lymphatic drainage becomes insufficient, lymph seeks alternative pathways of decompression. This maladaptive decompression explains why the same underlying circulatory problem can produce different clinical syndromes depending on the site of leakage [1,2,5].

  1. Intestinal lymphatic leakage leads to protein-losing enteropathy (PLE).
  2. Bronchial or mediastinal lymphatic leakage leads to plastic bronchitis.
  3. Pleural lymphatic leakage leads to chylothorax.

These manifestations should therefore be understood not as isolated complications, but as organ-specific expressions of a common Fontan-associated lymphatic disorder [1,2,5]. (PubMed)

3. Major Clinical Manifestations

3.1 Protein-Losing Enteropathy

PLE develops when intestinal and mesenteric lymphatic congestion causes loss of protein-rich lymph into the gastrointestinal tract. Clinically, patients may present with edema, ascites, pleural effusions, diarrhea, malnutrition, growth failure, hypoalbuminemia, and lymphopenia [2,6]. In many patients, PLE signals advanced Fontan circulatory stress and is often associated with unfavorable hemodynamics, reduced functional reserve, and poorer long-term outcomes [2,6]. (PubMed)

3.2 Plastic Bronchitis

Plastic bronchitis is caused by abnormal lymphatic leakage into the airways, resulting in the formation of branching bronchial casts. Patients may present with chronic cough, wheezing, recurrent respiratory distress, or even acute airway obstruction [2,6]. Beyond its direct respiratory effects, plastic bronchitis can further destabilize Fontan physiology by worsening pulmonary mechanics and increasing resistance to already passive pulmonary blood flow [2,6]. (PubMed)

3.3 Chylothorax

Chylothorax reflects leakage of lymph into the pleural space and may occur early after surgery or later in the course of Fontan failure. Persistent chylous drainage contributes to nutritional depletion, immune compromise, respiratory burden, and prolonged hospitalization [1,5]. As with PLE and plastic bronchitis, chylothorax is best viewed as part of the same lymphatic failure spectrum rather than a separate disease process [1,5]. (PubMed)

4. Contemporary Diagnostic Approach

A modern evaluation of Fontan lymphatic failure requires both hemodynamic and lymphatic assessment.

  1. Hemodynamic evaluation

    2. Fontan pathway obstruction, elevated pulmonary vascular resistance, ventricular dysfunction, atrioventricular valve regurgitation, and arrhythmias may all aggravate lymphatic failure and should be actively sought.

  2. Laboratory and organ-specific evaluation

    3. Serum albumin, total protein, lymphocyte count, pleural fluid analysis, and stool alpha-1 antitrypsin can help define the phenotype and severity of disease.

  3. Advanced lymphatic imaging

    4. One of the most important recent advances has been the use of heavily T2-weighted MR lymphatic imaging and dynamic contrast MR lymphangiography. These techniques allow visualization of abnormal thoracic duct anatomy, lymphatic perfusion patterns, collateral pathways, and leakage sites, and they have substantially improved both diagnostic precision and procedural planning [3-5]. MRI-based severity of lymphatic abnormalities has also been linked to worse clinical outcomes in Fontan patients [3,4]. (AHA Journals)

5. Principles of Management

Management should target the hemodynamic substrate first and the lymphatic abnormality second.

5.1 Hemodynamic Optimization

The foundation of therapy is to improve Fontan physiology whenever possible. This includes relieving anatomic obstruction, addressing atrioventricular valve regurgitation, treating arrhythmias, improving ventricular filling and output, and reducing pulmonary vascular resistance when appropriate [1,2]. Without improvement in the pressure environment, symptomatic therapies are often incomplete or temporary. (PubMed)

5.2 Supportive Therapy

Supportive treatment remains important and is tailored to the clinical phenotype:

  • PLE: nutritional optimization, protein replacement, diuretics, and selected medical therapies.
  • Plastic bronchitis: airway clearance, bronchoscopy when necessary, and cast-directed respiratory care.
  • Chylothorax: drainage, dietary fat restriction or medium-chain triglyceride-based strategies, and replacement of fluid and protein losses [2]. (PubMed)

5.3 Lymphatic Intervention

Recent progress in lymphatic intervention has changed the management landscape. Image-guided lymphatic embolization, thoracic duct decompression, and related catheter-based procedures now permit targeted treatment of abnormal lymphatic channels and leakage pathways [1,5]. These approaches have substantially improved outcomes in selected patients, particularly those with plastic bronchitis and PLE, and underscore the importance of multidisciplinary collaboration among cardiology, imaging, interventional, and surgical teams [1,5]. (PubMed)

6. Conceptual Summary

A useful conceptual framework is that the Fontan circulation places the lymphatic system under chronic afterload. Elevated CVP impairs lymphatic return, systemic venous congestion increases lymph production, and reduced cardiopulmonary energy transfer limits effective central drainage. When this imbalance becomes severe, lymph is redirected into the intestine, bronchi, or pleural space, producing PLE, plastic bronchitis, and chylothorax, respectively [1,2]. (PubMed)

7. Conclusion

Lymphatic failure in Fontan circulation is not a secondary or incidental phenomenon; it is a direct pathophysiologic consequence of the Fontan hemodynamic state. Chronically elevated venous pressure, increased lymphatic burden, and abnormal lymphatic remodeling together create a syndrome of impaired central drainage and pathologic leakage. Current understanding has shifted from viewing PLE, plastic bronchitis, and chylothorax as isolated complications to recognizing them as manifestations of a unified Fontan-associated lymphatic disorder. Advances in MR lymphatic imaging and targeted lymphatic intervention have significantly improved both diagnosis and management, making this an increasingly important field in contemporary Fontan care [1-5]. (PubMed)

References

[1] RochéRodríguez M, DiNardo JA. The Lymphatic System in the Fontan Patient-Pathophysiology, Imaging, and Interventions: What the Anesthesiologist Should Know. J Cardiothorac Vasc Anesth. 2022;36(8 Pt A):2669-2678.

[2] Mackie AS, Veldtman GR, Thorup L, Hjortdal VE, Dori Y. Plastic Bronchitis and Protein-Losing Enteropathy in the Fontan Patient: Evolving Understanding and Emerging Therapies. Can J Cardiol. 2022;38(7):988-1001.

[3] Udink Ten Cate FEA, Tjwa ETTL. Imaging the Lymphatic System in Fontan Patients. Circ Cardiovasc Imaging. 2019;12(4):e008972.

[4] Biko DM, DeWitt AG, Pinto EM, Morrison RE, Johnstone JA, Griffis H, et al. MRI Evaluation of Lymphatic Abnormalities in the Neck and Thorax after Fontan Surgery: Relationship with Outcome. Radiology. 2019;291(3):774-780.

[5] Smith CL, Krishnamurthy G, Srinivasan A, Dori Y. Lymphatic interventions in congenital heart disease. Semin Pediatr Surg. 2024;33(3):151419.

[6] Sharma VJ, Iyengar AJ, Zannino D, et al. Protein-losing enteropathy and plastic bronchitis after the Fontan procedure. J Thorac Cardiovasc Surg. 2021;161(6):2158-2165.e4.